TLCC
Twinlab Consolidated Holdings, Inc. [TLCC] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
TLCC Stock Summary
Top 10 Correlated ETFs
TLCC
Top 10 Correlated Stocks
TLCC
In the News
TLCC Financial details
Company Rating
Neutral
Market Cap
25.91M
Income
-17.44M
Revenue
48.36M
Book val./share
-0.49
Cash/share
0
Dividend
-
Dividend %
-
Employees
46
Optionable
No
Shortable
Yes
Earnings
29 Jun 2020
P/E
-1.49
Forward P/E
-
PEG
-0.9
P/S
0.54
P/B
-0.2
P/C
-
P/FCF
71.77
Quick Ratio
0.02
Current Ratio
0.08
Debt / Equity
-1.13
LT Debt / Equity
-0.03
-
-
EPS (TTM)
-0.07
EPS next Y
-
EPS next Q
-
EPS this Y
-45.06%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-16.9%
Revenue last 5Y
-6.42%
Revenue Q/Q
-3.37%
EPS Q/Q
46.51%
-
-
-
-
SMA20
-20%
SMA50
-20%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-103%
ROE
14%
ROC
0.03%
Gross Margin
25%
Oper. Margin
-6%
Profit Margin
-36%
Payout
-
Shs Outstand
259.09M
Shs Float
52.54M
-
-
-
-
Target Price
-
52W Range
0.05-0.2089
52W High
-
52W Low
-
RSI
20.79
Rel Volume
-
Avg Volume
596
Volume
Perf Week
0%
Perf Month
-20%
Perf Quarter
6.67%
Perf Half Y
6.67%
-
-
-
-
Beta
199.043
-
-
Volatility
0%, 0.01%
Prev Close
0%
Price
0.08
Change
0%
TLCC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.29 | 0.29 | 0.26 | 0.28 | 0.2 | |
| Net income per share | -0.08 | -0.17 | -0.06 | -0.06 | -0.03 | |
| Operating cash flow per share | -0.03 | -0.03 | -0.02 | 0.01 | -0.02 | |
| Free cash flow per share | -0.03 | -0.03 | -0.02 | 0.01 | -0.02 | |
| Cash per share | 0.02 | 0 | 0 | 0.01 | 0 | |
| Book value per share | -0.17 | -0.34 | -0.4 | -0.45 | -0.48 | |
| Tangible book value per share | -0.33 | -0.39 | -0.44 | -0.45 | -0.48 | |
| Share holders equity per share | -0.17 | -0.34 | -0.4 | -0.45 | -0.48 | |
| Interest debt per share | 0.37 | 0.4 | 0.43 | 0.43 | 0.43 | |
| Market cap | 127.14M | 15.34M | 25.73M | 26.92M | 19.43M | |
| Enterprise value | 206.45M | 106.2M | 127.97M | 126.93M | 121.14M | |
| P/E ratio | -6.23 | -0.34 | -1.79 | -1.8 | -2.36 | |
| Price to sales ratio | 1.73 | 0.21 | 0.39 | 0.37 | 0.37 | |
| POCF ratio | -19.37 | -1.82 | -5.08 | 10.16 | -4.51 | |
| PFCF ratio | -19.21 | -1.82 | -5.06 | 10.79 | -4.41 | |
| P/B Ratio | -2.9 | -0.17 | -0.25 | -0.23 | -0.16 | |
| PTB ratio | -2.9 | -0.17 | -0.25 | -0.23 | -0.16 | |
| EV to sales | 2.82 | 1.45 | 1.93 | 1.76 | 2.3 | |
| Enterprise value over EBITDA | -25.48 | -9.44 | -36.58 | 20.64 | 104.98 | |
| EV to operating cash flow | -31.45 | -12.63 | -25.24 | 47.9 | -28.1 | |
| EV to free cash flow | -31.19 | -12.6 | -25.14 | 50.87 | -27.47 | |
| Earnings yield | -0.16 | -2.9 | -0.56 | -0.55 | -0.42 | |
| Free cash flow yield | -0.05 | -0.55 | -0.2 | 0.09 | -0.23 | |
| Debt to equity | -2.62 | -1.35 | -1.34 | -1.21 | -1.17 | |
| Debt to assets | 1.62 | 3.89 | 3.92 | 5.71 | 6.99 | |
| Net debt to EBITDA | -9.79 | -8.07 | -29.23 | 16.26 | 88.14 | |
| Current ratio | 0.3 | 0.14 | 0.13 | 0.13 | 0.11 | |
| Interest coverage | -1.44 | -1.45 | -0.6 | 0.56 | 0.01 | |
| Income quality | 0.32 | 0.19 | 0.35 | -0.18 | 0.52 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0.33 | 0.22 | 0.14 | 0.24 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.55 | 0.43 | 0.35 | 0.02 | 0.01 | |
| Capex to operating cash flow | 0.01 | 0 | 0 | -0.06 | 0.02 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.02 | -0.01 | -0.01 | -0.12 | -0.09 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.56 | 1.16 | 0.71 | 0.77 | 0.59 | |
| ROIC | -0.28 | -0.61 | -0.18 | 0.42 | 0 | |
| Return on tangible assets | -0.64 | -2.59 | -0.63 | -0.62 | -0.4 | |
| Graham Net | -0.39 | -0.43 | -0.49 | -0.5 | -0.53 | |
| Working capital | -69.51M | -101.85M | -114.69M | -119.39M | -127.05M | |
| Tangible asset value | -82.99M | -100.94M | -114.22M | -117.67M | -125.43M | |
| Net current asset value | -85.83M | -101.85M | -119.76M | -124.59M | -131.09M | |
| Invested capital | -1.95 | -1.04 | -1 | -0.89 | -0.82 | |
| Average receivables | 7.55M | 7.45M | 7.38M | 7.65M | 5.49M | |
| Average payables | 9.11M | 7.2M | 5.51M | 5.38M | 6.33M | |
| Average inventory | 12.56M | 7.26M | 6.44M | 6.06M | 7.61M | |
| Days sales outstanding | 42.66 | 31.51 | 46.35 | 34.84 | 28.49 | |
| Days payables outstanding | 48.99 | 37 | 31.01 | 39.76 | 63.2 | |
| Days of inventory on hand | 48.17 | 38.5 | 41.46 | 38.23 | 89.79 | |
| Receivables turnover | 8.56 | 11.58 | 7.88 | 10.48 | 12.81 | |
| Payables turnover | 7.45 | 9.86 | 11.77 | 9.18 | 5.78 | |
| Inventory turnover | 7.58 | 9.48 | 8.8 | 9.55 | 4.07 | |
| ROE | 0.47 | 0.51 | 0.14 | 0.13 | 0.07 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.05 | 0.06 | 0.06 | 0.04 | 0.03 | |
| Net income per share | -0.01 | -0.02 | -0.02 | -0.01 | -0.02 | |
| Operating cash flow per share | -0.02 | 0 | -0.01 | 0.01 | 0 | |
| Free cash flow per share | -0.02 | 0 | -0.01 | 0.01 | 0 | |
| Cash per share | 0.01 | 0 | 0 | 0 | 0 | |
| Book value per share | -0.45 | -0.46 | -0.47 | -0.48 | -0.49 | |
| Tangible book value per share | -0.45 | -0.46 | -0.47 | -0.48 | -0.49 | |
| Share holders equity per share | -0.45 | -0.46 | -0.47 | -0.48 | -0.49 | |
| Interest debt per share | 0.41 | 0.41 | 0.42 | 0.4 | 0.4 | |
| Market cap | 25.91M | 31.09M | 28.24M | 19.43M | 25.91M | |
| Enterprise value | 128.63M | 133.92M | 133.46M | 121.14M | 127.1M | |
| P/E ratio | -4.15 | -1.85 | -1.41 | -1.45 | -1.32 | |
| Price to sales ratio | 1.96 | 2.15 | 1.82 | 2.08 | 2.87 | |
| POCF ratio | -5.61 | -114.73 | -10.63 | 6 | 106.62 | |
| PFCF ratio | -5.6 | -85.42 | -10.63 | 6.19 | 106.62 | |
| P/B Ratio | -0.22 | -0.26 | -0.23 | -0.16 | -0.2 | |
| PTB ratio | -0.22 | -0.26 | -0.23 | -0.16 | -0.2 | |
| EV to sales | 9.71 | 9.25 | 8.6 | 12.97 | 14.09 | |
| Enterprise value over EBITDA | 53.82 | 3.83K | -231.3 | -117.27 | -283.07 | |
| EV to operating cash flow | -27.84 | -494.17 | -50.23 | 37.41 | 523.04 | |
| EV to free cash flow | -27.8 | -367.91 | -50.23 | 38.59 | 523.04 | |
| Earnings yield | -0.06 | -0.13 | -0.18 | -0.17 | -0.19 | |
| Free cash flow yield | -0.18 | -0.01 | -0.09 | 0.16 | 0.01 | |
| Debt to equity | -1.2 | -1.2 | -1.2 | -1.17 | -1.13 | |
| Debt to assets | 5.91 | 6.12 | 5.9 | 6.99 | 8.59 | |
| Net debt to EBITDA | 42.98 | 2.94K | -182.36 | -98.46 | -225.37 | |
| Current ratio | 0.12 | 0.12 | 0.13 | 0.11 | 0.08 | |
| Interest coverage | 1.15 | -0.12 | -0.42 | -0.64 | -0.34 | |
| Income quality | -16.74 | 0.12 | 0.91 | -0.97 | -0.09 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.23 | 0.22 | 0.21 | 0.36 | 0.28 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | |
| Capex to operating cash flow | 0 | 0.34 | 0 | -0.03 | 0 | |
| Capex to revenue | 0 | -0.01 | 0 | -0.01 | 0 | |
| Capex to depreciation | -0.02 | -0.33 | 0 | -0.37 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.25 | 0.41 | 0.45 | 0.38 | 0.46 | |
| ROIC | -0.67 | -0.03 | -0.08 | -0.1 | -0.11 | |
| Return on tangible assets | -0.07 | -0.18 | -0.2 | -0.16 | -0.29 | |
| Graham Net | -0.5 | -0.51 | -0.52 | -0.53 | -0.54 | |
| Working capital | -119.12M | -121.44M | -124.01M | -127.05M | -129.85M | |
| Tangible asset value | -117.36M | -119.55M | -122.45M | -125.43M | -128.24M | |
| Net current asset value | -124.04M | -126.07M | -128.34M | -131.09M | -133.59M | |
| Invested capital | -0.89 | -0.87 | -0.87 | -0.82 | -0.79 | |
| Average receivables | 6.69M | 6.05M | 6.52M | 5.76M | 3.25M | |
| Average payables | 4.23M | 3.49M | 4.91M | 5.94M | 5.79M | |
| Average inventory | 6.72M | 8.74M | 10.21M | 9.98M | 8.43M | |
| Days sales outstanding | 44.11 | 34.89 | 43.05 | 39.56 | 23.87 | |
| Days payables outstanding | 24.56 | 38.38 | 38.61 | 92.1 | 65.59 | |
| Days of inventory on hand | 77.72 | 82.92 | 77.61 | 130.85 | 98.59 | |
| Receivables turnover | 2.04 | 2.58 | 2.09 | 2.27 | 3.77 | |
| Payables turnover | 3.67 | 2.34 | 2.33 | 0.98 | 1.37 | |
| Inventory turnover | 1.16 | 1.09 | 1.16 | 0.69 | 0.91 | |
| ROE | 0.01 | 0.04 | 0.04 | 0.03 | 0.04 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
TLCC Frequently Asked Questions
What is Twinlab Consolidated Holdings, Inc. stock symbol ?
Twinlab Consolidated Holdings, Inc. is a US stock , located in Boca raton of Fl and trading under the symbol TLCC
What is Twinlab Consolidated Holdings, Inc. stock quote today ?
Twinlab Consolidated Holdings, Inc. stock price is $0.08 today.
Is Twinlab Consolidated Holdings, Inc. stock public?
Yes, Twinlab Consolidated Holdings, Inc. is a publicly traded company.
Company Profile
- Volume Average 596
- Market Capitalization 25.91M
- Employee 46
- CEO Mr. Kyle Casey
- Headquarters Boca Raton,FL,US
- IPO Date 2015-05-07
-
Website
https://www.tchhome.com 
Twinlab Consolidated Holdings, Inc., together with its subsidiaries, manufactures, markets, distributes, and retails nutritional supplements and other natural products in the United States and internationally. The company offers vitamins, minerals, resveratrol, collagen, keratin, specialty supplements, and sports nutrition products under the Twinlab brand; healthy aging and beauty products under the Reserveage Nutrition and ResVitale brands; diet and energy products under the Metabolife; and a line of herbal teas under the Alvita brand. It also acts as contract manufacturer for private label customers. The company sells its products in various formulations and delivery forms, including capsules, tablets, softgels, chewables, liquids, stick packs, sprays, and powders primarily through health and natural food stores, supermarkets, mass market retailers, specialty stores retailers, online retailers, and websites. Twinlab Consolidated Holdings, Inc. was founded in 2013 and is based in Boca Raton, Florida.
